Hematologic Malignancies: Where Do We Stand in 2011?

Kantarjian, H., Schiffer, C. and Burnett, Alan Kenneth 2011. Hematologic Malignancies: Where Do We Stand in 2011? Journal of Clinical Oncology 29 (5) , pp. 473-474. 10.1200/JCO.2010.33.8897

Full text not available from this repository.

Abstract

Major advances in understanding the biology of hematologic malignancies and the development of new therapies are occurring at a rapid pace, and Journal of Clinical Oncology (JCO) is committed to offering the oncology community and oncology experts the most up-to-date information pertinent to our research and practice. In this context, it became clear that an issue of JCO dedicated to updating the pathophysiology, molecular pathogenesis, and therapies of leukemias and myelodysplastic syndrome (MDS) would be valuable.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Grune and Stratton
ISSN:	0732-183X
Last Modified:	25 Jun 2017 03:28
URI:	https://orca.cardiff.ac.uk/id/eprint/29425

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item